1 – 10 of 56
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2018
-
Mark
Cerebrospinal fluid biomarker levels: Total tau and phosphorylated tau as markers for rate of progression in Alzheimer’s disease.
2018) Advances in Alzheimer’s and Parkinson’s Therapies (AAT-AD/PD) Focus Meeting 2018(
- Contribution to conference › Abstract
-
Mark
Short-term response to cholinesterase inhibitors in Alzheimer’s disease delays time to nursing home placement
(
- Contribution to journal › Article
- 2017
-
Mark
Response to the Letter From Abid Iraqi, MD, CMD and Terry Hughes, RN, CS
(
- Contribution to journal › Letter
-
Mark
Levels of cerebrospinal fluid biomarkers total tau and phosphorylated tau do not predict survival time after diagnosis of Alzheimer’s disease – An 18-year follow-up.
2017) 10th Clinical Trials Conference on Alzheimer’s Disease(
- Contribution to conference › Poster
-
Mark
The course and end-points of Alzheimer’s disease according to sociodemographics, apolipoprotein E genotype and cognitive ability.
2017) Alzheimer's Association International Conference (AAIC), 2017(
- Contribution to conference › Poster
-
Mark
The outcomes of different assessment scales can predict survival in patients with Alzheimer’s disease
2017) 13th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2017) In Neurodegenerative Diseases 17(Suppl. 1). p.27-27(
- Contribution to journal › Published meeting abstract
- 2016
-
Mark
Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy.
(
- Contribution to journal › Article
-
Mark
Short-term response to cholinesterase inhibitors in Alzheimer’s disease delays time to nursing home placement.
2016) 14th International Athens/Springfield Symposium on Advances in Alzheimer Therapy In Neurobiology of Aging 39(Suppl. 1). p.2-2(
- Contribution to journal › Published meeting abstract
-
Mark
Cholinesterase inhibitors do not alter the length of stay in nursing homes among patients with Alzheimer's disease : A prospective, observational study of factors affecting survival time from admission to death.
(
- Contribution to journal › Article
-
Mark
Cholinesterase inhibitor therapy does not affect time spent in nursing homes in patients with Alzheimer’s disease.
2016) Alzheimer’s Association International Conference 2016(
- Contribution to conference › Poster